Feil Family Brain and Mind Research Institute

The roots of addiction risk may lie in how young brains function long before substance use begins, according to a new study from Weill Cornell Medicine.

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell Medicine investigators.

A three-year, $4.5 million grant from BD²: Breakthrough Discoveries for thriving with Bipolar Disorder to Weill Cornell Medicine investigators, in collaboration with Stanford Medicine, will support a three-pronged research project to map the brain circuits that contribute to mood shifts in bipolar disorder and help develop personalized therapies for the condition.

Researchers have discovered that free radicals generated at a specific site in non-neuronal brain cells called astrocytes, may promote dementia, according to a Weill Cornell Medicine study.

The grant supports the launch of a natural history study for a rare neurodevelopmental disorder that causes developmental delays and seizures. 

Dr. Teresa Sanchez, associate professor of pathology and laboratory medicine and associate professor of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, has been awarded the highly competitive Established Investigator Award from the American Heart Association.

Using an algorithm they call the Krakencoder, researchers at Weill Cornell Medicine are a step closer to unraveling how the brain’s wiring supports how we think and act.

Weill Cornell Medicine researchers have found that intracranial hemorrhages, or "brain bleeds," caused by a ruptured blood vessel in the brain doubles a person’s risk of developing dementia later in life.

After years of research, Dr. Gary Gibson’s work has culminated in a nationwide clinical trial evaluating an entirely new treatment approach for slowing Alzheimer’s progression.

Inhibiting an immune signaling protein called TLR7 may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer’s disease and ordinary aging, suggests a study led by researchers at Weill Cornell Medicine.

Increasing the levels of chemicals naturally produced in the body called endocannabinoids may thwart the highly addictive nature of opioids such as morphine and oxycodone while maintaining the drugs’ ability to relieve pain, according to a new preclinical study by Weill Cornell Medicine investigators.

Weill Cornell Medicine investigators have found that two genetic variants that confer high risk of Alzheimer’s disease (AD) together trigger a harmful inflammatory response in the brain’s immune cells, particularly in females, in a preclinical model.

A new study by Weill Cornell Medicine researchers helps explain why having ApoE4—the gene variant most closely linked to Alzheimer’s disease—increases the risk of neurodegeneration and white matter damage. 

By repeatedly scanning the brains of a small group of patients for a year and a half, Weill Cornell Medicine researchers have identified a distinct pattern of neuronal interactions that appears to predispose some people to developing depression. 

With surprising frequency, patients with severe brain injury can show clear signs of cognitive function on brain scans in response to requests to carry out complex mental work, even when they can’t move or speak, according to an international study co-led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Molecular and physiological changes in space travelers reveal new targets for aerospace medicine and can guide new missions, according to the results of a massive international research endeavor by investigators at Weill Cornell Medicine, SpaceX, and other organizations.

Weill Cornell Medicine scientists have uncovered the first evidence that astrocyte receptors can trigger opposite effects on cognitive function in male and female preclinical models.

Investigators at Weill Cornell Medicine have assembled the most comprehensive atlas to date of messenger RNA (mRNA) variants in the mouse and human brain, which will be important in understanding brain development, neuron specialization and other brain functions.

 A multi-center, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to results reported by researchers at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

Researchers at Weill Cornell Medicine have painstakingly catalogued the cellular response to stroke in a preclinical model, identifying the immune cells involved and the roles they may play in the days and weeks following a stroke.